TrialCancer medicine2018

An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer.

Jeffrey L Vacirca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.